SIGA Technologies (SIGA) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed SIGA Technologies (SIGA) over the past year, gaining 45.5% versus a loss of 58.9%. Over five years, SIGA leads with a -71.9% price change compared with -86.4% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($181.2 million vs $172.5 million), about 1.1 times the size, while SIGA Technologies is growing revenue faster (-31.8% vs -72.5%).
SIGA Technologies converts more of its revenue into profit, with a net margin of 24.6% versus -288.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | WHWK |
|---|---|---|
| Share price | $2.40 | $3.07 |
| Market cap | $172.45M | $181.16M |
| 1-day change | -9.43% | -1.60% |
| YTD return | -60.72% | +26.86% |
| 1-year return | -58.90% | +45.50% |
| 5-year return | -71.90% | -86.36% |
| P/E ratio (TTM) | 240.00 | — |
| Forward P/E | 5.45 | — |
| EPS (TTM) | $0.01 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $94.57M | $7.14M |
| Revenue growth (YoY) | -31.82% | -72.50% |
| Net income (latest FY) | $23.28M | $-20.60M |
| Gross margin | 68.59% | 89.36% |
| Operating margin | 25.06% | -1601.12% |
| Net margin | 24.61% | -288.26% |
| 52-week high | $7.11 | $5.50 |
| 52-week low | $2.30 | $2.10 |
| Distance from 52-week high | -66.24% | -44.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +35.42% | +151.14% |
| Average volume | 617.60K | 348.68K |
| Shares outstanding | 71.86M | 59.01M |
| Employees | 49 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed SIGA by 104.4 percentage points over the past year.
- SIGA Technologies is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -288.3 cents for Whitehawk Therapeutics.
- SIGA Technologies grew revenue faster in its latest fiscal year (-31.82% vs -72.50%).
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
SIGA vs WHWK FAQ
Which is bigger, SIGA Technologies or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $181.16M compared with $172.45M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, SIGA or WHWK?
WHWK returned +45.50% over the past 12 months, compared with -58.90% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are SIGA Technologies and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.